Human Gene Patents and Human Dignity

By genetics, healthcare workers are increasingly able to identify, treat and prevent more than 4000 genetic diseases and diseases inherited by our species. Genetics is central to diagnosis and treatment, especially in the detection of susceptibility and treatment. By 2025, the genetic condition may undergo thousands of diagnostic procedures and treatments. Genetic diagnosis can detect behavioral trends such as Down's syndrome and certain diseases such as depression.

Human Growth Hormone Gene is one of the latest patents granted to the US company Human Genome Sciences (HGS). HGS has filed a patent application covering over 1 million partial human gene sequences. HGS has partnered with at least 10 major pharmaceutical companies to provide access to human genetic information and genetic information. This proves that the opinion of the views of human patent applications as "American issues" has not been proven to be only partially correct. Yes, this is a matter of the US, but it is spreading all over the world. The Flinders Medical Center in Australia seeks a patent monopoly on human cell lines (part of the diagnostic test for autoimmune disease) on five continents

There was controversy in 1991 when a single patent application of 337 human genes was made in the United States and in February 1992 the NIH applied for an additional 2,375 genetic patents (Macer, 1992a) . Modern technology can sequencing all 100,000 human genes within a few years. However, since it has not been proved effective, such widespread use is expected to fail regardless of ethical or policy problems. These patents were filed on behalf of the National Institutes of Health, but many of the National Institutes of Health opposed it (Roberts, 1992). Government agencies may allow certain US companies to study these genes to 'protect' the US biotechnology industry from international competition.

Particular parts of the genome do not lead to commercialization of the whole human body and do not threaten our respect for human lives and human dignity. Patents or copyrights of individual genes are not harmful than patents or copyrights of artificial body parts (such as artificial skin, blood or heart valves). Thus, copyrights and patents can be extended to specific parts of the genome, but should not apply to the entire genome. However, there may be some legitimate reasons to regulate gene patents and copyright markets to prevent landslide effects. For example, we choose to restrict the sale of human genes for the purpose of genetic engineering alone, prohibit people and companies from acquiring the whole genome, prevent enterprises from monopolizing human genes We may take action

Commercialization of Human Reproductive Materials University of East Carolina at Gribeville, North Carolina David B Resznik Medical School